NCT05926102 The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
| NCT ID | NCT05926102 |
| Status | Recruiting |
| Phase | — |
| Sponsor | VA Office of Research and Development |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2024-02-01 |
| Primary Completion | 2029-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 5,000 participants in total. It began in 2024-02-01 with a primary completion date of 2029-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and which men have significant prostate cancer needing treatment. False-positive screening tests can result in unnecessary prostate biopsies for men who do not need them. However, new genetic testing might help identify which men are at highest risk for prostate cancer. This study will examine whether a genetic test helps identify men at risk for significant prostate cancer while helping men who are at low risk for prostate cancer avoid unnecessary biopsies. If this genetic test proves beneficial, it will improve the way that healthcare providers screen male Veterans for prostate cancer.
Eligibility Criteria
Inclusion Criteria: * baseline age 55-69 years * receipt of regular VA care * Veteran status Exclusion Criteria: * personal history of prostate cancer * prior prostate biopsy, prostatectomy, or prostate MRI * known carrier status of rare variant associated with cancer syndrome
Contact & Investigator
Jason L Vassy, MD MPH
PRINCIPAL INVESTIGATOR
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
Frequently Asked Questions
Who can join the NCT05926102 clinical trial?
This trial is open to male participants only, aged 55 Years or older, up to 69 Years, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05926102 currently recruiting?
Yes, NCT05926102 is actively recruiting participants. Contact the research team at charles.brunette@va.gov for enrollment information.
Where is the NCT05926102 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT05926102 clinical trial?
NCT05926102 is sponsored by VA Office of Research and Development. The principal investigator is Jason L Vassy, MD MPH at VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA. The trial plans to enroll 5,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.